LiverMultiScan v5

by Perspectum  · Based in United Kingdom → — A new way to see precision health. We deliver advanced imaging solutions that can help doctors make better decisions, personalize care for patients, and ensure better outcomes.
Gastroenterology Radiology

Overview

LiverMultiScan v5 by Perspectum is an advanced, non-invasive magnetic resonance diagnostic device software application designed for comprehensive liver evaluation. It utilizes multiparametric MRI to quantify key biomarkers of liver health, including liver fat (Proton Density Fat Fraction – PDFF), iron (Liver Iron Concentration – LIC), and fibroinflammatory activity (corrected T1 – cT1). The software processes DICOM 3.0 compliant MR image datasets from compatible MR systems to generate, display, and review 2D medical image data and pixel maps. LiverMultiScan v5 includes machine-learning based automatic processing for artifact detection and liver segmentation, generating a summary report for clinician interpretation. It aims to provide a complete picture of liver health, aiding in the diagnosis, assessment of disease severity, and monitoring of chronic liver diseases, potentially serving as a non-invasive alternative to liver biopsy.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Quantitative measurement of liver fat (PDFF).
  • Quantitative measurement of liver iron concentration (LIC).
  • Quantitative measurement of fibroinflammatory activity (cT1).
  • Non-invasive, MRI-based assessment.
  • Standardized, reproducible, and repeatable metrics across MRI scanner platforms.
  • Machine-learning for automatic artifact detection and liver segmentation.
  • Generates easy-to-understand patient-centric reports.
  • Prognostic value for liver and cardiovascular outcomes.
  • Cost-effective compared to alternative methods like biopsy.
  • Widespread insurance coverage in the US.

Use Cases

  • Diagnosis and monitoring of chronic liver disease.
  • Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
  • Evaluating liver health in patients with diabetes and cancer.
  • Guiding treatment decisions and monitoring treatment response.
  • Risk stratification for liver and cardiovascular outcomes.
  • Alternative to liver biopsy for liver tissue characterization.

What Physicians Need to Know

Real-Time Endoscopy AI
LiverMultiScan v5 is an MRI-based software for liver assessment and does not function as a real-time endoscopy AI tool. Real-time endoscopy AI systems are designed to provide immediate feedback during procedures, helping to identify abnormalities and improve diagnostic accuracy.
Adenoma Detection Rate Improvement
LiverMultiScan v5 is not involved in colonoscopy procedures or adenoma detection. AI-assisted colonoscopy systems have demonstrated an increase in adenoma detection rates by approximately 20% and a reduction in missed adenomas by 55% across multiple randomized trials.
Capsule Endoscopy AI
LiverMultiScan v5 is an MRI-based software for liver assessment and is not related to capsule endoscopy AI.
Procedure Documentation
LiverMultiScan v5 provides quantitative reports of liver health metrics derived from MRI scans. These reports include patient information, scan acquisition details, and the quantified metrics (cT1, PDFF, LIC).
Quality Metrics Tracking
LiverMultiScan v5 provides quantitative metrics for liver health, including corrected T1 (cT1) for fibro-inflammation, Proton Density Fat Fraction (PDFF) for liver fat, and Liver Iron Concentration (LIC). These metrics are standardized and validated for assessing liver disease. The software also incorporates automated liver segmentation and region of interest (ROI) placements for quantitative assessment.
Endoscopy System Compatibility
LiverMultiScan v5 is compatible with Siemens, GE, and Philips MRI machines at both 1.5 and 3 Tesla. It utilizes existing manufacturer software and DICOM 3.0 compliant magnetic resonance image datasets.
Physician Tip

LiverMultiScan v5 is a non-invasive MRI-based tool that provides quantitative metrics for assessing liver health, including fibro-inflammation (cT1), fat content (PDFF), and iron concentration (LIC). These metrics should be interpreted by a trained clinician in conjunction with other diagnostic tools and the patient's medical history to form a diagnosis. The report is not intended to be the sole basis for diagnosis, treatment decisions, or surgical planning. LiverMultiScan can be used to monitor patients with conditions like autoimmune hepatitis and MASLD/MASH, aiding in risk stratification and treatment response assessment. It is a contrast-free scan and can be combined with other MRI protocols.

LiverMultiScan v5 leverages existing DICOM image exchange platforms for automated data transfer, with native support for systems like Ambra and Powershare. It is designed to work with DICOM 3.0 compliant MRI datasets. The software is approved for use on Siemens, GE, and Philips MRI machines (1.5T and 3T) and uses existing manufacturer software, requiring only configuration. The service is hosted across regional data centers, ensuring data security with ISO 27001 certification.

Details

Category Gastroenterology AI, Radiology & Imaging AI
Pricing Unknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Unknown
Integrations
EHR Not specified
Specialties Gastroenterology, Radiology

What the Web Says

LiverMultiScan v5 is a non-invasive diagnostic software application that utilizes MRI data to quantify liver fat, iron content, and fibroinflammation, aiding physicians in the diagnosis and management of liver diseases like NASH and AIH. It is designed to be an additional supporting tool for diagnosis, not a replacement for comprehensive clinical evaluation. The software has shown promise in improving patient understanding of their condition and offering a cost-effective alternative to more invasive procedures like liver biopsy.

Overall: Positive

Strengths

  • Non-invasive, reducing risks and discomfort associated with liver biopsies.
  • Provides quantitative metrics for liver fat (PDFF), iron content (LIC), and fibroinflammation (cT1) simultaneously.
  • Aids in clinical decision-making and patient management plans.
  • Can improve patient understanding of their liver disease.
  • Demonstrated cost-effectiveness compared to traditional methods like liver biopsy.
  • Outperforms some other non-invasive techniques for identifying high-risk NASH patients.

Limitations

  • Not intended to replace established procedures for assessing liver health; interpretation by a trained physician is crucial.
  • Metrics should not be used as the sole basis for diagnostic decisions.
  • Very high liver iron concentration or fat content can reduce accuracy.
  • Patients with metal implants, pacemakers, or who are pregnant may not be able to undergo the MRI.
  • Potential for sampling bias in ROI selection, especially with heterogeneous fat distribution.
  • Not intended for morphological, anatomical, structural, or radiological assessment of images, or for assessing incidental findings.

Based on reviews from: perspectum.com, nih.gov, auntminnie.com, parikhradiology.com, fda.gov, thieme-connect.com, ed.ac.uk, kcl.ac.uk, preprints.org

Last updated: 2026-10-31

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate LiverMultiScan v5

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

perspectum.com
LiverMultiScan v5.1 CH, EU, UK, US – A Guide to Interpreting LiverMultiScan Reports for Physicians (v15.1 CURRENT) [ENG]
This document, updated January 8, 2024, provides a guide for physicians on interpreting LiverMultiScan v5 (LMSv5) reports, detailing its intended use as a magnetic resonance diagnostic device software for non-invasive liver evaluation and quantification of MR relaxation times.
2024-01
fda.gov
Premarket Notification K213960
The FDA's 510(k) Premarket Notification for LiverMultiScan v5 (LMSv5) from September 6, 2022, indicates its use as a magnetic resonance diagnostic device software application for non-invasive liver evaluation.
2022-09
nih.gov
State of the Art Quantification of Liver Iron with MRI - Vendor Implementation and Available Tools - PMC
This review article from NIH, published in 2023, discusses various MRI-based methods for quantifying liver iron concentration, referencing LiverMultiScan v5 (LMSv5) as an FDA-approved technique for non-invasive liver evaluation.
2023-01
thieme-connect.com
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol
This article, published in 2026, explores the potential of multiparametric MRI protocols, including LiverMultiScan v5.0, as a non-invasive method for assessing Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), aiming to reduce the need for liver biopsies.
2026-01
preprints.org
Probabilistic Neural Network for Hepatic Steatosis Quantification with Uncertainty Estimates from Single In-Phase MRI Images
A preprint from March 2026 introduces a novel probabilistic neural network framework for quantifying hepatic steatosis with uncertainty estimates using single in-phase MRI images, referencing Perspectum's LiverMultiScan v5.1 as a guide for interpreting liver tissue characterization.
2026-03
mdpi.com
Probabilistic Neural Network for Hepatic Steatosis Quantification with Uncertainty Estimates from Single In-Phase MRI Images
This peer-reviewed article from May 2026 details a probabilistic neural network framework for hepatic fat quantification from MRI data, achieving a 94% agreement with ground truth and referencing LiverMultiScan v5.1 for physician guidance.
2026-05

Videos

Product demos, reviews, and walkthroughs for LiverMultiScan v5.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

LiverMultiScan v5 is a non-invasive MRI-based software that provides quantitative metrics of liver health, including corrected T1 (cT1) for fibro-inflammation, Proton Density Fat Fraction (PDFF) for fat content, and Liver Iron Concentration (LIC) for iron. These metrics aid gastroenterologists in evaluating liver tissue health in various liver disorders like NAFLD, hemochromatosis, and NASH, offering a non-invasive alternative to liver biopsy for diagnosis and monitoring.
LiverMultiScan v5 is a FDA-cleared Class II magnetic resonance diagnostic device software application. It is designed to utilize DICOM 3.0 compliant magnetic resonance image datasets from compatible MR systems. The software is intended for use by trained operators at Perspectum's image analysis center, with reports interpreted by clinicians.
Alternatives for non-invasive liver assessment include other MRI-based techniques like signal intensity ratio (SIR) and relaxometry (R2/R2*), with FerriScan® being a commercially available R2-based LIC reporting technique. Transient elastography (TE) and Enhanced Liver Fibrosis (ELF) tests are also established non-invasive methods. However, LiverMultiScan offers contemporaneous measurement of steatosis, iron, and fibro-inflammation with a high technical success rate.
While specific pricing for LiverMultiScan v5 is not publicly available, studies have indicated that using LiverMultiScan can be more cost-effective than liver biopsy for monitoring liver conditions. For instance, an early economic model showed potential cost savings when using multiparametric MRI (including LiverMultiScan) instead of biopsies for managing autoimmune hepatitis.
LiverMultiScan v5 should not be used as the sole basis for diagnosis; it provides measurements that supplement a physician's overall assessment, considering the patient's medical history and other diagnostic information. The software is intended for liver evaluation and should not be used for interpreting anything outside the liver. Additionally, LiverMultiScan images must be acquired before administering a contrast agent, as contrast can affect quantification.
Yes, LiverMultiScan is recognized in clinical guidelines by several organizations. As of March 2022, Carelon (formerly AIM Specialty Health) Clinical Guidelines deem it medically appropriate for managing chronic liver disease. It is also recognized by the American Association for the Study of Liver Diseases (AASLD), American Association of Clinical Endocrinology (AACE), and American Gastroenterological Association (AGA) for assessment in NAFLD.

Related Tools

AI Highlights
CapsoVision
Gastroenterology AI
AI Highlights is an AI-assisted reading tool for the CapsoCam Plus capsule endoscopy system, designed to reduce the time physicians spend reviewing small bowel capsule endoscopy studies by identifying and prioritizing images with suspected abnormal lesions.
GI Genius Module
Cosmo Artificial Intelligence - Ai, Ltd.
Gastroenterology AI
The GI Genius™ intelligent endoscopy module is an AI-powered system designed to assist physicians in the real-time detection of colorectal polyps during colonoscopy, acting as a "second set of eyes" to enhance visualization and improve detection rates.
Cologuard / Cologuard Plus
Exact Sciences
Gastroenterology AI
Cologuard and Cologuard Plus are FDA-approved, non-invasive stool DNA colorectal cancer screening tests from Exact Sciences for average-risk individuals aged 45 and older. Cologuard Plus offers enhanced accuracy and fewer false positives. These at-home tests detect DNA markers and blood in stool to identify early-stage colorectal cancer.
Deep Capsule
Digestaid - Artificial Intelligence Development SA
Gastroenterology AI
Deep Capsule is an AI software tool that assists in reviewing capsule endoscopy images by detecting and differentiating lesions, stratifying hemorrhagic potential, and highlighting clinically relevant frames for physician validation.
Pure-Vu
Motus GI
Gastroenterology AI
The Pure-Vu System is an FDA-approved device that facilitates intra-procedural cleansing of the GI tract to improve visualization during colonoscopies and gastroscopies, especially in cases of inadequate bowel preparation or GI bleeding.
aScope Gastro
Ambu
Gastroenterology AI
The Ambu aScope Gastro is a sterile, single-use gastroscope with advanced imaging and design features for a variety of endoscopic procedures in the upper GI tract, offering portability and eliminating reprocessing.

See all Gastroenterology AI tools →

More from Perspectum

Hepatica v1
Perspectum
Oncology AI
Hepatica v1 by Perspectum is an AI-driven clinical and surgical decision support tool that provides quantitative measurements and visualizations of liver health from MRI data, primarily for pre-surgical planning in liver cancer.
LiverMultiScan
Perspectum
Gastroenterology AI
LiverMultiScan by Perspectum is an FDA-cleared, non-invasive MRI-based AI tool that quantifies liver fat, iron, inflammation, and fibrosis to aid in the diagnosis and management of chronic liver diseases.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.